Zobrazeno 1 - 10 of 2 376 pro vyhledávání: '"Weisman Hf"'
1
Akademický článek
Shedding of membrane complement inhibitors CD59 and CD46 into the circulation is associated with poor prognosis in acute coronary syndrome patients: a cohort study.
Autor: Zhong, Baojun1 (AUTHOR), King, Ben1 (AUTHOR), Waziri, Homa1 (AUTHOR), Yndigegn, Troels2,3 (AUTHOR), Engelbertsen, Daniel4 (AUTHOR), Björkbacka, Harry4 (AUTHOR), Nilsson, Jan4 (AUTHOR), Goncalves, Isabel4 (AUTHOR), Blom, Anna M.1 (AUTHOR), Schiopu, Alexandru1,5,6 (AUTHOR) Alexandru.Schiopu@med.lu.se
Publikováno v: Journal of Translational Medicine. 11/10/2024, Vol. 22 Issue 1, p1-10. 10p.
Zobrazit plný text záznamu
2
Akademický článek
Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody.
Autor: Moc Willeford, Courtney1 (AUTHOR) courtney.mocwilleford@certara.com, Shetty, Krithika1 (AUTHOR), Sheridan, Douglas2 (AUTHOR), Engler, Frank1 (AUTHOR)
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. Nov2024, Vol. 13 Issue 11, p2002-2015. 14p.
Zobrazit plný text záznamu
3
Diabetes Mellitus, Glycoprotein IIb/IIIa Blockade, and Heparin
Autor: Eric J. Topol, Weisman Hf, Keaven M. Anderson, A.M. Lincoff, Dean J. Kereiakes, Neal S. Kleiman, David P. Miller, Frank V. Aguirre, Robert M. Califf
Publikováno v: Circulation. 97:1912-1920
Background —After angioplasty, major complications and ischemic events occur more frequently in diabetic than nondiabetic patients. To determine whether treatment with abciximab is effective in reducing these events in diabetics, we analyzed charac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12e2aabbdb464fd60e398a885be86fdf
https://doi.org/10.1161/01.cir.97.19.1912
Zobrazit plný text záznamu
4
Abciximab Therapy and Unplanned Coronary Stent Deployment
Autor: James E. Tcheng, David P. Miller, Keaven M. Anderson, Catherine F. Cabot, Eric J. Topol, A.M. Lincoff, Robert M. Califf, Weisman Hf, Dean J. Kereiakes
Publikováno v: Circulation. 97:857-864
Background —The clinical and angiographic demographics of patients requiring unplanned coronary stent deployment and the optimal adjunct pharmacotherapy in this population are not well described. This report details the EPILOG trial experience with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c5928cb1c6ec939c2fe3510182eaf7d
https://doi.org/10.1161/01.cir.97.9.857
Zobrazit plný text záznamu
5
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
Autor: Stephen G. Ellis, Russell J. Ivanhoe, Weisman Hf, James J. Ferguson, E.J. Topol, Ann L. Wang, Neal S. Kleiman, Robert M. Califf, Keaven M. Anderson, James E. Tcheng, David P. Miller
Publikováno v: JAMA: The Journal of the American Medical Association. 278:479-484
CONTEXT Abciximab, a monoclonal antibody fragment against the platelet receptor alphaIIb beta3 integrin, prevents platelet aggregation. A randomized, placebo-controlled study showed that abciximab improves outcomes for patients undergoing percutaneou
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707bdafeb4dc710f352a64a3711455f0
https://doi.org/10.1001/jama.278.6.479
Zobrazit plný text záznamu
6
Akademický článek
Qili Qiangxin capsule attenuates myocardial fibrosis by modulating collagen homeostasis post-infarction in rats.
Autor: Sun, Minyan1 (AUTHOR), Liu, Chunhua1 (AUTHOR), Gao, Kehan1 (AUTHOR), Xu, Xingming1 (AUTHOR), Chen, Kunhan1 (AUTHOR), Qiu, Liang1,2 (AUTHOR) liangqiu@jxutcm.edu.cn, Wang, Xiaomin1 (AUTHOR) wangxm2001@163.com
Publikováno v: PLoS ONE. 9/27/2024, Vol. 19 Issue 9, p1-17. 17p.
Zobrazit plný text záznamu
7
Akademický článek
Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial.
Autor: Liao, Jia1,2 (AUTHOR), Qiu, Miaohan1 (AUTHOR), Feng, Xiaojian3 (AUTHOR), Chen, Kui4 (AUTHOR), Zhang, Dingbao5 (AUTHOR), Zou, Yuncheng6 (AUTHOR), Zheng, Xiaohui7 (AUTHOR), Zhao, Gang8 (AUTHOR), Tian, Nailiang9 (AUTHOR), Zheng, Zeqi10 (AUTHOR), Peng, Xiaoping10 (AUTHOR), Yang, Qing11 (AUTHOR), Liang, Zhenyang1 (AUTHOR), Li, Yi1 (AUTHOR) doctorliyi@126.com, Han, Yaling1 (AUTHOR) hanyaling@163.net, Stone, Gregg W.12 (AUTHOR)
Publikováno v: BMC Medicine. 9/27/2024, Vol. 22 Issue 1, p1-12. 12p.
Zobrazit plný text záznamu
10
711-5 Mechanism of Benefit of Platelet lib/ilia Receptor Inhibition in High Risk Angioplasty in the EPIC Trial: A Hierarchical Endpoint Analysis
Autor: Keaven M. Anderson, Eric J. Topol, Jeffrey Lefkovlts, Weisman Hf, Epic Investigators
Publikováno v: Journal of the American College of Cardiology. 25(2)
The EPIC trial demonstrated the potent platelet IIb/1l1a inhibitor, c7E3 reduced the incidence of acute complications in high risk angioplasty. The primary endpoint was a composite of death, myocardial infarction (MI), repeat urgent PTCA or CABG, and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c7472281dd0bf453ab8704b426cf9d5
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje